Search

Your search keyword '"Meca Lallana, V."' showing total 111 results

Search Constraints

Start Over You searched for: Author "Meca Lallana, V." Remove constraint Author: "Meca Lallana, V."
111 results on '"Meca Lallana, V."'

Search Results

1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

2. Documento de consenso de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple y manejo holístico del paciente 2023

Catalog

Books, media, physical & digital resources

4. Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study

7. Information-Seeking Strategies of People with Multiple Sclerosis in Spain: The INFOSEEK-MS Study

8. Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

10. 20415. USO DE SIPONIMOD EN PACIENTES CON ESCLEROSIS MÚLTIPLE SECUNDARIA PROGRESIVA EN PRÁCTICA CLÍNICA. ESTUDIO RESYZE

12. 20252. ESTUDIO MULTICÉNTRICO SOBRE LA INCIDENCIA, PRESENTACIÓN CLÍNICA Y FACTORES DE RIESGO DE LA NEUROTOXICIDAD ASOCIADA A LA TERAPIA CON CÉLULAS CART ANTI-CD19 EN ESPAÑA: WORK IN PROGRESS

13. 20835. OZANIMOD EN PACIENTES NAÏVE CON ESCLEROSIS MÚLTIPLE REMITENTE RECURRENTE LEVE-MODERADA: CARACTERÍSTICAS DE LA ENFERMEDAD EN EL ESTUDIO APPREZIATE

15. 20403. NIVELES SÉRICOS DE NEUROFILAMENTOS DE CADENA LIGERA COMO FACTOR PREDICTOR DE RESPUESTA EN UNA COHORTE MULTICÉNTRICA DE PACIENTES CON ESCLEROSIS MÚLTIPLE TRATADOS CON OCRELIZUMAB

17. Expert-Agreed Practical Recommendations on the Use of Cladribine

18. Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis

19. Deciphering Multiple Sclerosis Progression

20. Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

21. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry

22. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

23. Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

24. PND22 Discover Study, First Analysis Specific for Secondary Progressive Multiple Sclerosis Burden and Cost in Spain: Interim Analysis Results

25. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis

28. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial

32. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

33. Expert-Agreed Practical Recommendations on the Use of Cladribine

34. Cognitive impairment in multiple sclerosis: diagnosis and monitoring

35. Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis

36. Deciphering Multiple Sclerosis Progression

37. Observational study of gadolinium-enhancing lesions in MRI in patients with multiple sclerosis from the Spanish Mediterranean coast: Seasonal variability and relationship with climatic factors.

38. Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

39. Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.

40. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

41. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?

42. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

43. [XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

44. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis.

45. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.

46. Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs.

47. [15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].

48. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study.

49. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

50. Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program?